For many people with diabetes, lowering LDL cholesterol is just as important as controlling blood sugar. However, not everyone reaches their cholesterol goals with statins alone, and injectable PCSK9 inhibitors can be inconvenient or intimidating. Now, a new option has arrived. The FDA has approved the first oral PCSK9 inhibitor, …
Read More »Farxiga Just Went Generic—Will Lower Prices Finally Change Diabetes Care?
For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …
Read More »When Cardiology Meets Endocrinology: Why Diabetes Care Is Becoming a Team Sport
Not long ago, diabetes management focused primarily on controlling blood glucose levels. Today, that approach has evolved dramatically as cardiologists and endocrinologists increasingly work together to reduce cardiovascular risk. Thanks to groundbreaking cardiovascular outcome trials (CVOTs), clinicians now understand that treating type 2 diabetes means protecting the heart, kidneys, and …
Read More »Rethinking Sugar-Free: Are Artificial Sweeteners Raising Cardiovascular Risk?
For years, artificial sweeteners have been promoted as an important strategy for reducing sugar intake in people with diabetes. They help lower carbohydrate intake, reduce post-meal glucose spikes, and support weight management without adding calories. However, recent research has challenged the long-held assumption that all non-nutritive sweeteners are metabolically neutral. …
Read More »Incretin Therapy Selection in High-Risk Patients: What New Outcomes Data Suggest
Choosing the right treatment for patients with both diabetes and heart disease can feel like walking a tightrope. With evolving evidence, the role of incretin therapy in cardiovascular disease management is now at the center of clinical decision-making. Recent cardiovascular outcomes trials have shifted how clinicians think about therapy selection, …
Read More »Incretin Therapy in Cardiovascular Disease: Should Treatment Selection Change After New Outcomes Data?
In recent years, the role of incretin therapy in cardiovascular disease management has gained attention as new outcomes data reshape how clinicians approach high-risk patients. But should treatment choices really change based on these findings? As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular …
Read More »GLP-1s and Atrial Fibrillation: Do These Drugs Influence Cardiac Rhythm Risk?
The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …
Read More »GLP-1s and Peripheral Artery Disease: Can Metabolic Therapy Improve Limb Outcomes?
GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …
Read More »GLP-1 Drugs and Cardiovascular Inflammation: A New Pathway for Risk Reduction?
Why do some patients still face heart risks even after managing blood sugar and cholesterol? This lingering issue has led researchers to explore how GLP-1 therapies may influence cardiovascular inflammation as a possible missing link. While traditional treatments focus on glucose and lipid control, growing evidence suggests inflammation may continue …
Read More »GLP-1 Drugs and Blood Pressure: Why These Diabetes Medications Lower More Than Glucose
When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.